AU2020904824A0 - Treatment for Coronavirus infection and associated cytokine toxicity (2) - Google Patents
Treatment for Coronavirus infection and associated cytokine toxicity (2)Info
- Publication number
- AU2020904824A0 AU2020904824A0 AU2020904824A AU2020904824A AU2020904824A0 AU 2020904824 A0 AU2020904824 A0 AU 2020904824A0 AU 2020904824 A AU2020904824 A AU 2020904824A AU 2020904824 A AU2020904824 A AU 2020904824A AU 2020904824 A0 AU2020904824 A0 AU 2020904824A0
- Authority
- AU
- Australia
- Prior art keywords
- treatment
- coronavirus infection
- associated cytokine
- cytokine toxicity
- toxicity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010053983 Corona virus infection Diseases 0.000 title 1
- 230000001988 toxicity Effects 0.000 title 1
- 231100000419 toxicity Toxicity 0.000 title 1
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/910,220 US20230120864A1 (en) | 2020-03-12 | 2021-03-12 | Treatment for coronavirus infection and associated cytokine toxicity |
EP21767048.8A EP4117683A4 (en) | 2020-03-12 | 2021-03-12 | Treatment for coronavirus infection and associated cytokine toxicity |
AU2021234945A AU2021234945A1 (en) | 2020-03-12 | 2021-03-12 | Treatment for coronavirus infection and associated cytokine toxicity |
CN202180031179.5A CN115484964B (en) | 2020-03-12 | 2021-03-12 | Treatment of coronavirus infection and related cytokine toxicity |
CA3171235A CA3171235A1 (en) | 2020-03-12 | 2021-03-12 | Treatment for coronavirus infection and associated cytokine toxicity |
JP2022554820A JP2023517239A (en) | 2020-03-12 | 2021-03-12 | Treatment of coronavirus infection and associated cytokine toxicity |
KR1020227035531A KR20220159397A (en) | 2020-03-12 | 2021-03-12 | Treatment for coronavirus infection and related cytokine toxicity |
BR112022018200A BR112022018200A2 (en) | 2020-03-12 | 2021-03-12 | TREATMENT FOR CORONAVIRUS INFECTION AND ASSOCIATED CYTOKINE TOXICITY |
PH1/2022/552298A PH12022552298A1 (en) | 2020-03-12 | 2021-03-12 | Treatment for coronavirus infection and associated cytokine toxicity |
PCT/AU2021/050215 WO2021179047A1 (en) | 2020-03-12 | 2021-03-12 | Treatment for coronavirus infection and associated cytokine toxicity |
CL2022002457A CL2022002457A1 (en) | 2020-03-12 | 2022-09-08 | Treatment of coronavirus infection and cytokine-associated toxicity |
US18/071,800 US11938146B2 (en) | 2020-03-12 | 2022-11-30 | Treatment for coronavirus infection and associated cytokine toxicity |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2020904824A0 true AU2020904824A0 (en) | 2021-01-21 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021188969A3 (en) | Coronavirus vaccines and methods of use | |
EP3912623C0 (en) | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm | |
WO2005000878A3 (en) | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | |
UA88463C2 (en) | Pharmaceutical composition comprising compound i and method of treating hiv infection | |
EP4117683A4 (en) | Treatment for coronavirus infection and associated cytokine toxicity | |
EP4117630A4 (en) | Treatment of coronavirus infection | |
EP4121022A4 (en) | Compositions and methods for treating and preventing a coronavirus infection | |
EP4186496A4 (en) | Application of cannabidiol in treatment of coronavirus infections | |
EP4199950A4 (en) | Methods and compositions for treating coronavirus infections | |
WO2023122260A3 (en) | Inhibitors of sars-cov-2 | |
IL277315B (en) | Methods and composition for treating coronavirus infection | |
EP4093758A4 (en) | Methods and compositions for treating and preventing viral infection | |
EP4216961A4 (en) | Compositions and methods for treatment of coronavirus infection | |
EP4178575A4 (en) | Compositions and methods for inhibiting and treating coronavirus infections | |
WO2022053993A3 (en) | Treatments for sars-cov-2 infection (covid-19) | |
EP4121038A4 (en) | Compositions and methods for the treatment of coronavirus infection and respiratory compromise | |
AU2020904824A0 (en) | Treatment for Coronavirus infection and associated cytokine toxicity (2) | |
EP4164619A4 (en) | Treatment methods and formulations | |
EP4157327A4 (en) | Compositions and methods for preventing and treating sars-cov-2 infection | |
EP4074310A4 (en) | Drug for treating coronaviral and retroviral infections and hepatitis c | |
AU2020900751A0 (en) | Treatment for coronavirus infection and associated cytokine toxicity | |
MX2023009041A (en) | Use of proteasome inhibitors in the treatment of coronavirus infections. | |
WO2023003951A3 (en) | Compositions and methods for the treatment of herpes simplex virus infection | |
EP4009981A4 (en) | Method and compositions for treating coronavirus infection | |
EP4103192A4 (en) | Compositions and methods for treating coronavirus infections |